A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

• Conditions: Non-Small Cell Lung Cancer

• Registration Number: NCT00073151
• Lead Sponsor: Abbott

Brief Summary

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-09
• Study First Submitted: 2003-11-17
• Study First Submitted QC: 2003-11-17
• Study First Posted: 2003-11-18
• Study Completion: 2006-01
• Status Verified: 2007-11
• Last Update Submitted: 2007-11-28
• Last Update Posted: 2007-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Objective Response Rate in subjects with NSCLC	1 year

Secondary Outcome Measures

Name	Time	Method
Survival	2 years
Time to Tumor Progression (TTP)	1 year
Toxicities associated with treatment administration	1 year

Trial Locations

Locations (16)

Dayton Oncology and Hematology; 🇺🇸 Kettering, Ohio, United States

Oncology Hematology Group of South Florida; 🇺🇸 Miami, Florida, United States

Oncology & Hematology Associates of Kansas City, PA; 🇺🇸 Kansas City, Missouri, United States

Washington University School of Medicine; 🇺🇸 St. Louis, Missouri, United States

University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States

University of Maryland Greenbaum Cancer Center; 🇺🇸 Baltimore, Maryland, United States

Albany Regional Cancer Center; 🇺🇸 Albany, New York, United States

Cancer Centers of the Carolinas; 🇺🇸 Greenville, South Carolina, United States

University of Wisconsin Comprehensive Cancer Center; 🇺🇸 Madison, Wisconsin, United States

Cancer Care Associates; 🇺🇸 Oklahoma City, Oklahoma, United States

Northwest Cancer Specialists; 🇺🇸 Vancouver, Washington, United States

West Cancer Clinic; 🇺🇸 Memphis, Tennessee, United States

Cancer Care Northwest; 🇺🇸 Spokane, Washington, United States

Texas Oncology; 🇺🇸 Ft. Worth, Texas, United States

Florida Cancer Institute; 🇺🇸 New Port Richey, Florida, United States

Raleigh Hematology Oncology; 🇺🇸 Cary, North Carolina, United States